FDA — authorised 15 September 2009
- Application: ANDA065386
- Marketing authorisation holder: HOSPIRA INC
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Piperacillin And Tazobactam in United States
FDA authorised Piperacillin And Tazobactam on 15 September 2009
Marketing authorisations
FDA — authorised 21 October 2010
- Application: ANDA065362
- Marketing authorisation holder: SANDOZ
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 21 October 2010
- Application: ANDA065363
- Marketing authorisation holder: SANDOZ
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 May 2011
- Application: ANDA065498
- Marketing authorisation holder: EUGIA PHARMA SPECLTS
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 31 May 2011
- Application: ANDA065523
- Marketing authorisation holder: ISTITUTO BIO ITA SPA
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 31 May 2011
- Application: ANDA090498
- Marketing authorisation holder: ISTITUTO BIO ITA SPA
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 29 October 2014
- Application: ANDA203557
- Marketing authorisation holder: SANDOZ
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 13 January 2017
- Application: ANDA207847
- Marketing authorisation holder: MILLA PHARMS
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 13 January 2017
- Application: ANDA207848
- Marketing authorisation holder: MILLA PHARMS
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 March 2017
- Application: ANDA207146
- Marketing authorisation holder: APOTEX
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 May 2018
- Application: ANDA203720
- Marketing authorisation holder: FRESENIUS KABI
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 18 May 2018
- Application: ANDA203719
- Marketing authorisation holder: FRESENIUS KABI
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 10 August 2018
- Application: ANDA204959
- Marketing authorisation holder: SHANDONG
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 29 July 2019
- Application: ANDA212287
- Marketing authorisation holder: ASTRAL
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 16 February 2021
- Application: ANDA208675
- Marketing authorisation holder: SAGENT PHARMS INC
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 16 February 2021
- Application: ANDA208674
- Marketing authorisation holder: SAGENT PHARMS INC
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 12 October 2023
- Application: ANDA217409
- Marketing authorisation holder: EUGIA PHARMA
- Local brand name: PIPERACILLIN AND TAZOBACTAM
- Indication: INJECTION — POWDER,FOR SOLUTION
- Status: approved
FDA — authorised 3 April 2025
- Application: NDA206056
- Marketing authorisation holder: B BRAUN MEDICAL
- Local brand name: PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
- Indication: POWDER — INTRAVENOUS
- Status: approved
FDA
- Status: approved
Pricing & reimbursement
- annual_list: USD 80000.00 per year
Piperacillin And Tazobactam in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is Piperacillin And Tazobactam approved in United States?
Yes. FDA authorised it on 15 September 2009; FDA authorised it on 21 October 2010; FDA authorised it on 21 October 2010.
Who is the marketing authorisation holder for Piperacillin And Tazobactam in United States?
HOSPIRA INC holds the US marketing authorisation.
What does Piperacillin And Tazobactam cost in United States?
annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.